Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma-Reference-Cited by-同舟云学术

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma

Published:2017 Issue:1 Volume:2 Page:e000168
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Patil Vijay Maruti,Noronha Vanita,Joshi Amit,Choughule Anuradha Bharat,Bhattacharjee Atanu,Kumar Rajiv,Goud Supriya,More Sucheta,Ramaswamy Anant,Karpe Ashay,Pande Nikhil,Chandrasekharan Arun,Goel Alok,Talreja Vikas,Mahajan Abhishek,Janu Amit,Purandare Nilendu,Prabhash Kumar

Funder

Tata Memorial Hospital

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer;Pao;Nat Rev Cancer,2010

2. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer;Takeda;Lung Cancer,2015

3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

5. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisão Sistemática de Estudos Observacionais sobre o uso de Erlotinibe e Gefitinibe no Tratamento do Câncer de Pulmão de Células Não Pequenas;Revista Brasileira de Cancerologia;2024-08-30

2. Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial;Journal of Clinical Oncology;2024-08-05

3. Uniqueness of lung cancer in Southeast Asia;The Lancet Regional Health - Southeast Asia;2024-08

4. Reduced frequency dosing of osimertinib in EGFR-mutant non-small cell lung carcinoma: real world data;ecancermedicalscience;2024-06-28

5. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis;Targeted Oncology;2024-06-01